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Abstract
microRNA expression signatures can differentiate normal and breast cancer tissues and can define specific clinico-
pathological phenotypes in breast tumors. In order to further evaluate the microRNA expression profile in breast cancer, we
analyzed the expression of 667 microRNAs in 29 tumors and 21 adjacent normal tissues using TaqMan Low-density arrays.
130 miRNAs showed significant differential expression (adjusted P value=0.05, Fold Change=2) in breast tumors compared
to the normal adjacent tissue. Importantly, the role of 43 of these microRNAs has not been previously reported in breast
cancer, including several evolutionary conserved microRNA*, showing similar expression rates to that of their corresponding
leading strand. The expression of 14 microRNAs was replicated in an independent set of 55 tumors. Bioinformatic analysis of
mRNA targets of the altered miRNAs, identified oncogenes like ERBB2, YY1, several MAP kinases, and known tumor-
suppressors like FOXA1 and SMAD4. Pathway analysis identified that some biological process which are important in breast
carcinogenesis are affected by the altered microRNA expression, including signaling through MAP kinases and TP53
pathways, as well as biological processes like cell death and communication, focal adhesion and ERBB2-ERBB3 signaling. Our
data identified the altered expression of several microRNAs whose aberrant expression might have an important impact on
cancer-related cellular pathways and whose role in breast cancer has not been previously described.
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Introduction
microRNAs (miRNAs) are small non coding RNAs which
regulate the expression of coding genes at a post-transcriptional
level through inhibition and destabilization of messenger RNAs
[1]. MicroRNAs participate in diverse biological processes like cell
division, proliferation, differentiation, death, growth and develop-
ment, stem cell regulation, metabolism and stress response [2,3].
Aberrant expression of microRNAs is related with the
development of different pathologies, including cancer, where
they can act either as tumor suppressors or as ‘‘oncomirs’’
(oncogenes). Approximately 50% of the microRNA genes are
located in regions commonly affected by chromosomal alterations
(amplification, deletions and fragile sites) in the cancer genome [4].
As in the case of messenger RNA expression patterns, microRNA
expression signatures can also be used to classify human tumors
and to identify molecular signatures associated with relevant
clinical characteristics [5,6]. During the biogenesis of microRNAs,
an intermediate RNA duplex represents an obligatory intermedi-
ate. After the maturation process, the mature, leading strand is
preferentially incorporated into the silencing complex, while the
role of the other strand (miRNA*) was regarded as a simple
passenger. However bioinformatic and functional analyses have
identified important regulatory roles of the miRNA*, both in
normal and in pathological states, including cancer [7].
In breast cancer, analysis of microRNA expression patterns has
led to the identification of signatures which can differentiate tumor
from normal tissues [8,9]. Analysis of the messenger RNA targets
of microRNAs with differential expression in normal and tumor
breast tissues, indicates that their aberrant expression impact the
regulation of important cellular networks known to drive breast
cancer [10]. This is supported by the observation that several
clinically relevant breast tumor features, such as tumor size, nodal
involvement, vascular invasion, hormone receptor and HER2
status, are also related to the expression of particular microRNAs
[8,9,11]. Additionally, microRNAs might be used as markers of
the metastatic potential of primary breast tumors [12].
In order to further analyze the differences in microRNA
expression patterns in breast tumors, we evaluated the expression
profile of 667 microRNAs in 29 breast tumors compared to 21
adjacent normal tissues. We also compared the expression patterns
between four fresh frozen and their corresponding paraffin
PLoS ONE | www.plosone.org 1 March 2012 | Volume 7 | Issue 3 | e31904embedded tumor tissue pairs, in order to evaluate the robustness of
the TaqMan low density array platform as a tool for retrospective
studies.
Our analyses identified 130 differentially expressed microRNAs
between the tumor and normal tissues, 43 of them whose
involvement in breast cancer has not been previously described,
to our best knowledge. Differential expression of 14 of these
microRNAs was validated in an independent set of normal and
tumor samples, suggesting that their aberrant expression might
play important roles in breast cancer. Several evolutionary
conserved miRNA* were included in this expression signature,
showing expression rates similar to their mature strand, suggesting
their potential regulatory role in breast tumors.
Results
MicroRNA expression profiles in breast tumors
Comparative Ct analysis (2- DDCt) was used to identify a set of
130 microRNAs that were differentially expressed between the
normal and tumor tissue (adjusted P value#0.05, fold change: 2).
17 were over-expressed and 113 were down-regulated in the
tumor compared to the normal tissue (Table 1 shows the
microRNAs with the highest differential expression values, a
complete list including all 113 is shown in Table S1). This is in
accordance with other studies performed using different types of
platforms, such as bead-based flow cytometry [5] or miRNA
microarrays [13].
Unsupervised hierarchical clustering analysis of the log-
transformed delta Ct values of the differentially expressed
microRNAs, showed that this set of markers is able to differentiate
the tumors from the normal breast tissues (Figure 1, figure S1).
We observed an overlap between microRNAs expressed in
normal and tumor samples, indicating that miRNA expression
levels, rather than a differential tissue-specific pattern, is driving
the separation between normal and tumor tissue.
Identification of microRNAs with previously unknown
involvement in breast cancer
Out of the 130 differentially expressed microRNAs we detected
in this study, 43 (30%) have not been previously reported in the
literature as involved in breast cancer, to our best knowledge
(Table2).Some oftheserepresent thepassengerstrand(miRNA*)of
pre-miRNAs. In some cases, like miR-10b* and miR-145*, their
corresponding leading strand have important, proven roles in breast
cancer, but the role of the star strand has not been explored.
Interestingly, for most of the microRNA* included in our profile,
their guiding opposite strand is differentially expressed in the tumor
tissue, in most cases with a very similar expression rate (Figure 2).
The published and validated transcriptional targets (oncogenes,
estrogen regulators, tumor suppressors, miRNA biogenesis ma-
chinery and epigenetic master regulators) of the miRNAs with no
previous involvement in breast cancer, indicate that they might
have important biological implications in breast tumor biology
(Table 2).
Evaluation of the reproducibility of the microRNA
screening method
microRNA expression profiles were analyzed in a set of 29
breast tumor tissues compared to 21 normal, non paired, adjacent
tissues (clinical characteristics of these samples is presented in
Table 3). 23 tumors and two pools of normal samples were run in
triplicate to assess the reproducibility of the TaqMan low-density
array. The standard deviation between the technical triplicates was
0.1675507, while the Spearman Correlation was 97% (Max: 99%,
Min: 96%). The Spearman correlation as well as the standard
deviation values between our triplicates, showed a high correlation
between each technical and biological replicates (Figure S2).
Hormone receptor status is associated to the expression
of different microRNAs
Delta Ct analysis identified differential microRNA expression
signatures related with ER and PR status in the tumor samples.
ER+ tumors showed differential expression of miR-342-5p, miR-
29c*, miR-29b-2*, miR-30e, miR-190b, miR-769-5p, miR-30d
and miR-432, with a (P value #0.05) compared to ER- tumors
(Table 4, figure S3). Differential expression of miR-145*, miR-
Table 1. MicroRNAs with the highest differential expression
between normal and tumor breast tissue.
Genes Loci log2 fold change Adjusted P.value
miR-129-3p 11p11.2 223.86634845 0.0506
miR-668 14q32.31 215.87301587 0.04
miR-488 1q25.2 25.617314544 6.33E-06
miR-204 9q21.12 24.752087104 4.63E-07
miR-215 1q41 24.407307647 0.005803931
miR-139-3p 11q13.4 23.750253537 3.49E-05
miR-205 1q32.2 23.584191223 1.63E-05
miR-654-3p 14q32.31 23.321708086 0.003627753
miR-337-5p 14q32.2 23.27939216 0.00019613
miR-451 17q11.2 23.174627414 0.001302005
miR-504 Xq26.3 23.157463711 0.001762529
miR-518b 19q13.42 23.153532596 0.001739482
miR-483-5p 11p15.5 22.964422269 0.001296854
miR-497 17p13.1 22.958883061 4.03E-05
miR-486-3p 8p11.21 22.93777587 5.35E-05
miR-145 5q32 22.909161828 0.001369377
miR-543 14q32.31 22.874385872 2.07E-05
miR-99a 21q21.1 22.842203759 0.000378898
miR-874 5q31.2 22.829348053 0.000438618
miR-100 11q24.1 22.781736443 7.32E-05
miR-183* 7q32.2 5.93253603 0.010473616
miR-454* 17q22 5.252342351 0.000237826
let-7g* 3p21.1 4.984783172 0.038198527
miR-592 7q31.33 3.914412027 0.051848409
miR-190b 1q21.3 3.822193954 0.011638475
miR-449a 5q11.2 3.546100694 0.044712337
miR-760 1p22.1 3.231671879 0.058593441
miR-210 11p15.5 2.973935913 0.016929322
miR-148b* 7p15.2 2.786665283 0.000432485
miR-188-5p Xp11.23 2.55450304 0.034381478
miR-425 3p21.31 2.477271454 0.00683419
miR-877 5p15.1 2.226445287 0.010473616
miR-629* 15q23 2.188160454 0.056679644
miR-301b 22q11.21 2.033976085 0.036983438
miR-636 17q25.1 1.706601183 0.020686329
miR-21 17q23.1 1.271732126 0.052188036
doi:10.1371/journal.pone.0031904.t001
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discriminate between the PR+ from the PR- samples (Figure S4).
Analysis of the miRNA/miRNA* sequence conservation
Most of the miRNA/miRNA* pairs included in the expression
profile were conserved in the seed sequence region across the five
different vertebrate genomes we analyzed (Figure S5). Some of the
miRNA*, like miR-10b* and miR-30a* presented divergence in its
sequence, reflected in the percentage of nucleotide substitutions.
However, most of the miRNA/miRNA* showed a high degree of
evolutionary conservation of the passenger miRNA* strand with a
low percentage of nucleotide substitutions (miR-19b, miR-19b*,
miR-125, miR-125*, miR-26b, miR-26b*, miR-145, miR-145*,
miR-335, miR-335*, miR-214 and miR-214) (Figure S6). This
analysis determined that the miRNA* detected in our analyses is
both differentially expressed between the normal and tumor
tissues, in most cases with a very similar expression pattern
compared to the corresponding leading strand and is also
evolutionary conserved, suggesting that they might have a
biological role in breast cancer.
Figure 1. Unsupervised Hierarchical clustering analysis using the differentially expressed microRNAs separate normal and tumor
breast tissues. The heatmap (Spearman correlation, Euclidean distance) represents log transformed Delta Ct values. Heat map colors correspond to
microRNA expression as indicated in the color key: red (over-expressed) and green (down-regulated). Blue line: Control samples, red line: tumor
samples.
doi:10.1371/journal.pone.0031904.g001
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miRNA Validated targets miRNA Validated targets
miR-379 None reported miR-656 None reported
miR-433 FGFR1, FGF20, HDAC6, GRB2 miR-543 None reported
miR-655 None reported miR-10b* DICER1, ERBB2, EGFR, RHOC
miR-99a NFKB1,SLC12A2, DICER1, AKT1, MYC, IGF1 miR-145* DGCR8, KRAS, ADAM17, BCL2, ERBB2, DICER1,
miR-758 None reported miR-26b* CCDN1, BRCA1, NOTCH1, EZH2, DICER1, MYC, EPHA2
miR-874 None reported miR-30e* ERBB2, TGFBR2, CCND1
miR-127-3p BCL2, BCL6, MYC, NOTCH1, miR-30a* DICER1, ARL2, PRKCI, NOTCH1, SOX2
miR-135a JAK2, STAT3, PI3, miR-99a* None reported
miR-518b None reported miR-214* VEGFA, EZH2, MYC, PAK1, TWIST1, DICER1
miR-382 POMC, RUNX1, MECP2 miR-92a-1* TGFB1, IGFR1, BRCA2, MYC
miR-134 CREB1, YY1, SOX2, MDM4 miR-129-3p SOX4, MLH1
miR-889 None reported miR-215 ZEB2, ALCAM, MCL-1
miR-338-3p DICER1, ERCC4, HES5, MCM2, BRAF miR-488 None reported
miR-487b None reported miR-668 None reported
miR-455-5p TLR4, UCP1, MAPK3 miR-222* ETS1, TNF, AKT1, BCL2, DICER1, EPHB2
miR-361-5p TGFB1, TLR4, AKT1, IRS1 miR-454* None reported
miR-517a None reported miR-148b* IL6, TLR3, TLR4, APC
miR-539 HLCS miR-877 RNASEN
miR-512-3p CFLAR, CDKN1A, DNMT1 miR-183* PIK3CA, DICER1, FOXO1, PTEN. SAG
miR-491-5p FGFR1, NCOA6, FOSB, TNF miR-592 DICER1
miR-331-5p MDM2, SOAT1, ERBB2, JAG1 miR-425 DICER1, SMAD3, PDGFC
miR-136* CD36
doi:10.1371/journal.pone.0031904.t002
Figure 2. Comparison of the expression rate between miRNA-miRNA*. The bars show the normalized expression values of the microRNA
pairs: driver (microRNA) and passenger (miRNA*) strands present in the breast cancer profile.
doi:10.1371/journal.pone.0031904.g002
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independent set of breast tumor tissues
A set of 17 microRNAs was selected for further analysis in an
independent set of samples through evaluation of their expression
using independent TaqMan assays. This set included 13 micro-
RNAs with differential expression between the tumor and normal
tissues and 4 with non-differential expression. Expression profiles
were concordant in 14/17 (82.3%) of the selected microRNAs,
and only three failed to replicate. A similar expression value was
obtained for the same microRNA in both of the TLDA and the
single probe assay. (Pearson Correaltion: 97.3153%) (Table 5).
Deregulated microRNAs and their putative
transcriptional targets
To define potential mRNA targets of the differentially expressed
microRNAs, and their impact on cellular pathways, we performed
an mRNA target prediction analysis with at least 3 different
algorithms (Tables 6–7) followed by enrichment analysis of the
predicted mRNA targets using Diana, mir-Path and the Reactome
databases. The list of the top pathways ranked by the enrichment
P-value is presented in Table 8.
Comparison of microRNA profiles between Paraffin
embedded and fresh-frozen tissues
Formalin fixed paraffin embedded (FFPE) tissue represents a
major source of potentially useful biological material for retrospec-
tive analysis. To determine the performance and robustness of the
microRNA TLDA system in the analysis of microRNAs obtained
from FFPE tissues, we compared the expression patterns of pairs of
fresh-frozen and FFPE tissues from the same patient. Correlation
between these results was analyzed using Spearman correlation and
unsupervised hierarchical clustering. We observed cluster aggrega-
tion, as well as a high correlation value between the fresh and the
FFPE tissues obtained from the same patient (average 93.75%,
minimum of 90%; maximum of 98%), indicating that results
obtained from RNA isolated from FFPE tissues retain the same
expression signature as the fresh frozen tissue (Figure 3).
Discussion
Differentially expressed microRNAs with no previous
involvement and potential relevance in breast cancer
We have analyzed the microRNA expression patterns in a set of
breast cancer tumors and compared them to normal tissue. Our
Table 3. Clinical and pathological information of the sample collection.
ID ER PR Her2/neu AGE HISTOLOGY STAGE Tumor Size (cm) TNM
5 22+ 66 IDC IIB 3 pT2 pN1a M0
13 ++2 62 IDC I 1.5 T1c N0 M0
15 2 ++ 45 IDC IIIB 2.5 pT4b pN0 M0
30 + 22 89 IDC IIA 1.5 T1cN0M0
41 2 + 2 50 IDC I 1.5 T1N0M0
50 ++2 47 IDC IIA 2.5 pT2 pN0 M0
55 + 2 + 52 IDC I 2 pT1c pN0 M0
58 22+ 59 ISDC IIA 3.5 pT1mic pN1mic M0
71 + 22 39 IDC IIIA 1.9 pT1c pN2 M0
73 ++2 65 IDC IIIA 2 pT1c pN2 M0
74 2 + 2 47 IMC IIA 3.5 pT2 pN1a M0
75 22+ 50 IDC IIB 2.5 pT2 pN1a M0
79 + 22 56 IDC IIIA 2 pT1c pN2a M0
80 222 37 IDC IIA 2.5 pT2 N0 M0
81 2 + 2 48 IDC IIA 1.5 pT1c pN1a M0
82 + 22 59 IDC IIA 2.2 pT2 pN0 M0
97 222 56 IDC IIIA 4.7 pT2 pN2a M0
105 ++2 39 IDC IIIC 2.3 pT2 N3a M0
106 ++2 42 IDC I 1.6 pT1c pN0 M0
107 222 59 IDC IIA NA T1.N0M0
110 + 22 39 IDC IIB 3 T2N1Mx
122 222 51 IDC IIA 1.6 pT1c pN1a M0
123 ++2 71 IDC IIB 4.9 pT2 N1a M0
128 ++2 55 IDC IIA NA T2N1M0
129 ++2 53 IDC IIB 1.3 pT1c pN1a M0
142 2 + 2 47 ILC I 1.8 T1b N0M0
146 222 54 IDC IIA NA T2N0M0
149 + 22 61 IDC IIB 3 T2N0M0
150 ++2 49 IDC IIA 1.5 T2N0M0
IDC: Infiltrating ductal carcinoma, ISDC: In situ ductal carcinoma, ILC: Infiltrating lobular carcinoma, IMC: Infiltrating mucinous carcinoma, NA: Not available.
doi:10.1371/journal.pone.0031904.t003
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whose role in breast cancer has not been previously described, to
our best knowledge. Several evolutionary conserved miRNA* were
included in this expression signature, showing expression rates
similar to their mature strand. Differential expression of a set of
these microRNAS was validated in an independent set of tumor
and normal breast tissues, suggesting their potential regulatory role
in breast tumors.
Finally, we evaluated the performance of the TaqMan low-
density array through the comparison of microRNA expression
patterns obtained from fresh-frozen and FFPE tissue pairs,
obtaining similar results in both cases.
Table 4. Differentially expressed miRNAs associated with hormone receptor status.
Estrogen Receptor
miRNA Fold Change p.value Pathways of the mRNA targets
miR-342-5p 1.576048754 0.002539134 Cell cycle
miR-29c* 22.631736726 0.007378817
DNA replication
miR-30e 21.517276999 0.003742107
Cell surface interactions
miR-190b 3.822193954 0.001163848
miR-30d 1.305024162 0.005495711 Apoptosis
miR-432 1.110681182 0.003739888 Cell cycle check points.
Progesterone Receptor
miRNA Fold Change p.value Pathways of the mRNA targets
miR-145* 3.171062506 0.043296329 Apoptosis
miR-34a* 2.12616702 0.047844819 Cell cycle Check points
DNA repair
miR-193b* 3.125460441 0.05702715 Immune system
doi:10.1371/journal.pone.0031904.t004
Table 5. miRNAs selected for validation in an independent set of tumor and normal breast tissues.
Independent Assay TLDA
miRNA RQ P-Value RQ Adj.P-Value Validation
miR-129-3p 222.42152466 0.0509 223.86634845 0.0506 DR
miR-136* 25.641025641 0.0078 22.708003 3.85E-06 DR
miR-99a 23.883495146 0.0082 21.803093 0.013542569 DR
miR-10b 25.980861244 0.0484 22.090468209 0.000109373 DR
miR-206 22.070966521 0.009 22.355497628 0.0077 DR
miR-27a 23.58347292 0.0142 21.982850027 0.009750279 DR
miR-145 22.671898854 0.04141 22.90916182 0.001369377 DR
miR-21 2.2054 0.02749 1.271732126 0.052188036 OE
miR-184 6.672 0.2183 3.3103 0.169 NC
miR-24 21.804077215 0.1159 21.857355126 0.079 NC
miR-492 3.2652 0.0724 2.3677 0.1465 NC
miR-326 22.419549964 0.2573 22.578 0.678 NC
miR-488 26.954102921 0.0063 25.61731454 6.33E-06 DR*
miR-668 215.87301587 0.04 214.15451895 0.0019 DR*
miR-25* 3.4012 0.2661 20.581 0.0133 FP
miR-431 28.605851979 0.1159 2.2719 0.0576 FP
miR-149* 28.271298594 0.0033 10.269 0.0298 FP
DR: down-regulated, OR: over-expressed, DR*: down Regulated, but expressed in 78% of the samples, FP: False Positive.
doi:10.1371/journal.pone.0031904.t005
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breast cancer, we identified the down-regulation of miR-129-3p.
In mouse lung epithelial cells, lentiviral mediated expression of
miR-129-3p results in G1 phase arrest and cell death through
down-regulation of CDK6, ERK1 and ERK2, indicating its
activity in cell proliferation. Epigenetic repression of miR-129 also
Table 6. Differentially expressed microRNAs with no previous involvement in breast cancer and cellular pathways affected by their
transcriptional targets.
miRNA Status Cellular pathways related with cancer
miR-129-3p Down-regulated Regulation of BAD phosphorylationHs_the IGF-1 Receptor and Longevity, Hs_Role of ERBB2 in signal transduction and
oncology, breast cancer resistance to antimicrotubule agents and influence of RAS and RHO proteins on G1 to S
Transition
miR-488 Down-regulated CARM1 and regulation of the Estrogen Receptor
miR-139-5p Down-regulated Apoptosis, chromosome maintenance and transmembrane transport of small molecules.
miR-655 Down-regulated Apoptosis, signaling by VEGF, cell cycle membrane, metabolism of protein and signaling by insulin receptor.
miR-134 Down-regulated Transmembrane transport of small molecules and transcription
miR-136* Down-regulated Siganling by EGFR, signaling by Wnt, apoptosis, transcription, cell junction organization and signaling by VEGF. *
miR-874 Down-regulated Signalling by Notch, gene expression, cell cycle, mitotic and immune system**
miR-539 Down-regulated Apoptosis, signaling by insulin receptor, pyruvate metabolism and citric Acid (TCA) cycle, signaling of EGFR, steroid
hormones, cell cycle, mitotic and signaling by Notch.
miR-491-5p Down-regulated DNA replication, Signaling by notch, regulatory RNA pathway and signaling by EGFR
miR-889 Down-regulated Cell cycle, cell junction organization, membrane trafficking, metabolism of hormones and DNA repair**
miR-222* Down-regulated Transmembrane transport of small molecules, apoptosis, cell cycle, signaling by EGFR and cell cycle checkpoint ***
miR-877 Over-expressed Signaling by EGFR and cell junctions Organization
miR-425 Over-expressed EXT2 (possible tumor suppressor), MET receptor, PAK4. Cell cycle signaling, cell signaling checkpoints and transport of
small molecules and biological oxidation.
miR-454* Over-expressed Transmembrane transport of small molecules, membrane trafficking, apoptosis, cell cycle, and DNA replication*
miR-592 Over-expressed ERBB4, CD200, ST7. DNA replication, apoptosis, mRNA processing, transcription and metabolism of lipids
let-7g* Over-expressed Cell junction organization, apoptosis, Immune system, signaling by TGF beta and integration of energy metabolism**
miR-183* Over-expressed Transmembrane transport of small molecules, cell junction organization, signaling by VEGFR, and integration of energy
metabolism**
*mRNA targets predicted only with Miranda,
**mRNA targets predicted with Miranda and Targetscan,
***mRNA targets predicted with Miranda and Pictar.
doi:10.1371/journal.pone.0031904.t006
Table 7. Previously reported miRNAs with differential expression in breast cancer, some of their mRNA targets and the cellular
pathways where they participate.
miRNA Status Targets and cellular pathways related with cancer Bibliography
miR-125a/b Down-regulated Oncogene: ERBB2 and ERBB3. Signal transduction: MAP3K10 and MAP3K11. c-raf-1 [32]
miR-10b Down-regulated Growth factor: FLT and BDNF. Transducing factor :SHC1. Oncogene: Rho. Homeobox gene: HOXD10 [13]
let-7 Down-regulated Oncogene: RAS. Architectural factor: HMGA2 [13]
miR-205 Down-regulated Growth factor: TGF-b. HER3 phenotype. Oncogene: ErbB3 and Zeb1 [61]
miR-145 Down-regulated Kinase: RAF1. Oncogene: YES [13,62]
miR-31 Down-regulated Oncogene: Rho, Metastasis-promoting genes FZAD3, ITGA5, M-RIP. Regulate invasion and
metastasis. Patients with higher miR-31 expression, had prolonged survival.
[63]
miR-335 Down-regulated Oncogene: SOX4 and TNC. TNC (Tenascin C): responsible for the acquisition of metastatic properties [64]
miR-126 Down-regulated Growth factor: VEGF. Insulin receptor tyrosine kinase: IRS-1 [64]
miR-101 Down-regulated EZH2, oncogenic and metastatic activity [65]
miR-206 Down-regulated CARM1 and Regulation of the Estrogen Receptor, T Cell Receptor Signaling Pathway,
Regulation of BAD phosphorylation.
[66]
miR-222 Down-regulated ERa negatively modulates miR-222. Confers proliferative advantage and migratory activity
to cells and promote the transition from ER-positive to ER-negative tumors
[32]
miR-21 Over-expressed BCL-2, PTEN, MASPIN, involved in apoptosis [38]
miR-210 Over-expressed Overexpression is induced by hypoxia in a HIF-1a– and VHL-dependent manner. miR-210 influences
the hypoxia response by targeting a transcriptional repressor of the MYC-MAX pathway (6)
[67]
doi:10.1371/journal.pone.0031904.t007
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endometrial cancer [14]. In breast cancer, SOX1 is activated due
to the loss of miR-335, which was also found down-regulated in
our study (Table 1) suggesting that miR-129 might also play a role
in the SOX1 mediated acquisition of metastatic capacity [12,15].
Decreased expression of miR-215, down-regulated in our
expression profile, has been associated with cell proliferation rate
and has been proposed as a tumor suppressor candidate in colon
cancer. miR-215 reduces cell proliferation and cell cycle G2-arrest
through regulation of dihydrofolate reductase thymidylate syn-
thase (DTL), and increased expression of TP53 and p21 [16].
DTL has been implicated in cell proliferation, cell cycle arrest and
cell invasion in diverse tumor types, including hepatocellular
carcinoma and breast cancer [17].
We found down-regulation of some of the miR-99 family
members, including miR-99a, this has also been described in
advanced prostate cancer cell lines and tissues. The direct targets
of the miR-99 family are the chromatin remodeling factors
SMARCA5, SMARCD1 and the growth regulatory kinase
mTOR, which is also an important pathway activated in breast
cancer [18]. miR-99a, has also been found downregulated in
serous ovarian carcinoma [19].
Senescence represents a potent tumor suppressive mechanism,
and involvement of microRNAs in this process has been already
described. miR-668, down-regulated in head and neck squamous
cell carcinoma cell lines and in our expression profile, has been
identified as a senescence-inducing microRNAs, playing an
important role not only in cancer pathogenesis, but also as an
interesting target for the development of new therapeutic targets
[20].
Over-expression of mir-425 has been described in several
human cancer cells [21] and its pri-miRNA sequence is
evolutionarily conserved in different mammals (human, mouse,
dog and opossum) supporting the idea that miR-425 plays a
regulatory role in eukaryotic cells [22]. TargetScan, Mirtarget2,
Miranda, miRTar, PITA and RNA hybrid algorithms, predicted
DICER1 and SMAD2 as potential targets of miR-425. SMAD is
involved in the regulation of DROSHA, another key player in
small RNA processing [23], indicating that aberrant expression of
miR-425 might have important effects in the biogenesis of small
RNAs.
miR-592 was over-expressed in our tumor dataset. This
microRNA has been found differentially expressed between
DNA mismatch repair deficient and proficient colon tumors.
The interactions between miR-592 and genes associated with the
mismatch repair system suggest an oncogenic role of this miRNA,
possibly acting through inhibition of tumor suppressor genes [24].
Upregulation of miR-592 has also been reported as part of the
microRNA signature of kidney cancer [25].
miR-877 is a DROSHA independent intronic microRNA, up-
regulated in our breast tumor samples. It is part of the coding
region of the ATP-binding cassette subfamily F member 1
(ABCF1), which is over expressed in breast cancer. ABCF1 is a
transporter of molecules through membranes, and has been
associated to drug resistance and the development of some types of
cancer [26].
Together with this set of novel microRNAs, we also confirmed
the differential expression of microRNAs whose role and biological
targets in breast cancer have been well described (Table 5). This is
the case of the down-regulation of miR-125b [13,27], let-7
Table 8. Statistically significant biological pathways potentially affected by the differentially expressed microRNAs in breast
cancer.
Pathway
# of Genes
(Union) p-value Description (KEGG Pathway Database)
MAPK signaling pathway 130 0.0002488 Involved in cellular functions: cell proliferation, differentiation and migration.
Wnt signaling pathway 85 0.0000056 Required for developmental processes, cell proliferation and cell division.
Focal adhesion 100 0.000000193 Cell motility, cell proliferation, cell differentiation, regulation of gene expression and
cell survival
Adherens junction 47 0.0001819 Important for maintaining tissue architecture and cell polarity
TGF-beta signaling pathway 54 0.00001657 Regulates proliferation, apoptosis, differentiation and migration
Insulin signaling pathway 73 0.00001462 Allows Tyrosine phosphorylation of insulin receptor substrates
Regulation of actin cytoskeleton 100 0.0001411 Cell-matrix adhesions: cell motility, cell proliferation, cell differentiation, regulation of
gene expression and cell survival
ErbB signaling pathway 49 0.0001177 Regulates proliferation, differentiation, cell motility, and survival.
Ubiquitin mediated proteolysis 66 0.0000034 Signal for protein degradation
Gap junction 48 0.000826 Intercellular channels to communicate the cytosolic compartments with neighbor cells
Basal cell carcinoma 29 0.0000621 Common cancer related with epithelia
Calcium signaling pathway 71 0.0000547 Electrochemical gradient across the plasma membrane
VEGF signaling pathway 34 0.000047 Mediator of VEGF-driven responses, is a crucial signaling pathologic angiogenesis
Androgen and estrogen metabolism 8 0.0000361 Sexual hormones
Glycerophospholipid metabolism 31 0.0000344 Lipid metabolism
Hedgehog signaling pathway 26 0.0000332 Regulates stem cell proliferation
Cell Communication 33 0.000000329 Intercommunication between cells
Jak-STAT signaling pathway 59 0.0000213 Signaling mechanism of cytokines and growth factors
Tight junction 52 0.00186 Mediate cell adhesion
TP53 signaling pathway 28 0.00000157 Responses to stress signals, DNA damage, oxidative stress and activated oncogenes
doi:10.1371/journal.pone.0031904.t008
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PLoS ONE | www.plosone.org 9 March 2012 | Volume 7 | Issue 3 | e31904[5,13,28] miR-205 [29–31], miR-145 [13,31], miR10b [13], miR-
222 [32], miR34a [33], miR-31[34], miR-206 [12,13,35]; and
over-expression of miR-210 [13,36,37] and miR-21 [13,28,38]
(check reference [39] for a review).
As part of our expression profile we found an important
presence of miRNAs*. Recent bioinformatic and experimental
data show a high degree of conservation over vertebrate evolution,
particularly in the seed regions of expressed miRNAs* [7]. The
miRNA/miRNA* ratios also change in different developmental
stages [40] and have been involved in the regulation of different
biological networks in normal physiological conditions [41]. In
cancer, miRNA* expression has been detected in childhood acute
lymphoblastic leukemia [42], myelodysplastic syndrome [43], cell
lines of tumors of the female reproductive tract [44] and
melanoma [45] indicating their potential role in cellular
transformation. The set of miRNA* we found differentially
expressed between the normal and tumor breast tissues show a
high degree of evolutionary conservation, according to our analysis
in five animal genomes, as well as a similar expression rate than
their corresponding leading strand. These results suggest that these
miRNA* might be playing regulatory roles in breast cancer.
Breast cancer etiology includes genomic alterations that drive
cancer cell development, like loss of heterozygosity, amplifications,
deletions and fragile sites, which can promote oncogene activity or
repress the expression of tumor suppressors [46]. More than half of
the human miRNAs (60%) are located in regions commonly
affected in the cancer genome, a situation that might affect their
expression [4]. Our analysis identified down-regulation of 22
microRNAs located in the 14q32 region, which is deleted in
approx. 10% of breast tumors [20], and has been reported as a
chromosomal region where several breast cancer-related micro-
RNAs are located [47] (Figure S7), suggesting that loss of this
chromosomal region and the down-regulation of the miRNAs
codified in this locus, might be correlated in a fraction of breast
tumors.
Hormone receptor status is an important tumor characteristic to
classify breast cancer and to determine clinical treatment.
However, there is limited information about the genetic
mechanisms regulating the expression of hormone receptors. We
identified a set of miRNAs which can differentiate hormone
receptor positive and negative tumors. Analysis of the mRNA
targets of these miRNAs identified biological pathways relevant to
breast cancer, like apoptosis, DNA repair, cell cycle check-points,
etc. (Table 3). The miRNAs in the ER signature can directly
regulate transcripts like ESR1 (miR-342-5p, miR-190b, miR-432),
ESRRG (miR-30d, miR-30e), ESRRA (miR-432); ERN2 (miR-
342-5p), which induces translational repression in response to ER
stress, coactivators of the estrogen receptor like PELP1 (miR-342-
5p) and SRC (miR-342-5p); mediators of cell cycle trough estrogen
activation like E2F (miR-30d, miR-30e and miR-432) and
transcription factors like DP1 (miR-30e). While miRNAs of the
PR profile can regulate the activity of the progesterone receptors
PRDM4 (miR-34a*), PRDM16 (miR-145*) and co-activators of
the progesterone pathway like SRC (miR-34*, mir-145*) and
MAPK (miR-145*, miR-193*, miR-34*). miR-190 and miR-345
have already been reported as discriminators of ER status [47],
suggesting its importance in the establishment of this phenotype.
Deregulation of microRNA expression might potentially affect
the regulation of multiple cancer-related genes; for this reason it’s
important to define the biological networks affected by differen-
tially expressed microRNAs and their transcriptional targets.
Pathway analysis of our expression profile determined different
transcripts and protein-protein interactions, which can be
activated or repressed by these microRNAs. Examples of these
pathways are ERBB signaling, which plays a determinant role in
breast cancer [48] through its contribution to tumor development,
cellular transformation, involvement in the development of central
nervous system metastases and targeted therapy [49]. Another
important pathway affected by the differentially expressed
miRNAs is the mitogen-activated protein kinase (MAPK), which
is activated in breast cancer and is involved in the initiation and
pathogenesis of breast tumors [50]. Analysis of the targets affected
by the miRNAs with no previous relation with breast cancer
included in our signature, also identified several cancer-related
pathways, including KRAS, EGFR, MAPK, VEGF, ERBB,
PTEN, FOS, AKT1, etc. (Table 6, table 8, figure S8).
Finally, in order to evaluate the potential application of the
TLDA platform in the retrospective evaluation of miRNA
expression patterns in breast cancer, we carried out a comparison
between results obtained from fresh frozen and FFPE tissue.
Results of the comparison showed a high correlation between the
two tissues, indicating that the platform can be used in
retrospective studies using FFPE tissue [51].
Materials and Methods
Breast tissue samples and RNA extraction
After obtaining the written patient’s informed consent, tumor
and normal adjacent breast samples were collected during surgery
at the Institute of Breast Diseases (FUCAM) in Mexico City. The
protocol was reviewed and approved by the Ethics and Research
committees of the National Institute of Genomic Medicine and the
Institute of Breast Diseases in Mexico City (CE2009/11). Tissues
were macroscopically analyzed by a trained pathologist and stored
at 280uC until further processing. Frozen sample sections were
evaluated histologically to assure that only samples with more than
80% of tumor cells were included in our analyses. Frozen tissues
were disrupted with a Tissue Ruptor (Qiagen Inc., Valencia, CA)
and total RNA was obtained using the Trizol protocol (Invitrogen,
Carlsbad, CA). For the FFPE tissues, total RNA was isolated with
the Recoverall kit (Ambion, Austin, USA) according to the
manufacture’s protocol. Briefly, 10-8 mm sections were incubated
in xylene for 3 minutes at 50uC for de-paraffinization, followed by
two brief washes in 100% ethanol. Once ethanol was evaporated,
RNA extraction was done as described in the kit’s protocol. Total
RNA concentration was evaluated by spectrofotometry (Nano-
Drop Technologies, Wilmington, Delaware). Total RNA integrity
from the frozen samples was analyzed using the Agilent 2100
Bioanalyzer with the Nano-Eukariotic chip.
MicroRNA expression analysis
The Megaplex TLDA, v2.0 (TaqManH Low Density Array,
Applied Biosystems (ABI), Foster City, CA) platform was used to
measure miRNA expression. There are two plates in this system:
plate A, containing well-characterized and widely expressed
microRNAs, while plate B presents less characterized microRNAs.
The combined plates evaluate the expression of 667 unique
human specific microRNAs (present in V14 of the Sanger
miRBase) in parallel. Briefly, the procedure begins with the
retro-transcription of 70 ng of total RNA with stem-loop primers
Figure 3. Correlation between FFPE and fresh samples. A) Unsupervised hierarchical cluster of the delta Ct values of all the analyzed
microRNAs represented as a Heat Map. B) Scatter plot of the Ct values in pair-wise comparisons from fresh (T) and FFPE samples (TP).
doi:10.1371/journal.pone.0031904.g003
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in order to increase the concentration of the original material and
to detect microRNAs that are expressed at low levels. The pre-
amplified product was loaded into the TaqManH Low Density
Arrays and amplification signal detection was carried out using the
7900 FAST real time thermal cycler (ABI). A total of 29 tumor and
21 normal samples (two pools: one containing five normal samples,
other containing 12 normal samples, plus 4 independent normal
samples) were analyzed. 23 tumors and the two normal pools were
processed by triplicate, representing 82% of the total samples.
Raw miRNA expression data is available at the Gene Expression
Omnibus (GEO), with accession number GSE35412.
Statistical analysis
To determine the expression level of each miRNA, the
comparative Ct (2
2DDCt) method was used. RNU44 and
RNU48 showed the most stable expression between samples and
were selected for normalization across all experiments [52]. All
analyses were done using R (HTqPCR, gplots-bioconductor). The
Ct raw data (fractional cycles numbers at which the fluorescence
cross the threshold) was determined using an automatic baseline
and a threshold of 0.2. Samples with a Ct value of ,36 cycles
were excluded from the analyses and the normal tissue samples
were used as calibrators. A geometric mean was used to obtain the
media between replicates and the outliers among replicates were
excluded. A 2-fold change value obtained by the comparative Ct
method (2
2DCT) was used to determine the differentially expressed
microRNAs. An adjusted t-test was used to evaluate the
significance differences in the Ct values between controls and
tumors as well as between hormone receptor positive and
negatives tumors. Only microRNAs with an adjusted P value of
0.05, a fold change of 2 and consistent expression in at least 80%
of the samples were considered as differentially expressed.
Unsupervised clustering analysis, using Spearman correlation
and average linkage, was used to identify different sub-groups
defined by miRNA expression profiles. The rank-invariant
normalized data was evaluated through Spearman correlation
analysis between technical and biological replicates.
Analysis of potential mRNAs targeted by differentially
expressed microRNAs
Possible mRNA targets of the differentially expressed micro-
RNAs were identified using the mirDIP (2011) [53] and miRwalk
databases (2011) [54], through an integrative evaluation with
different algorithms: TargetScan v5.1 (http://www.targetscan.
org), PicTar (http://pictar.mdc-berlin.de), miRanda (www.
microrna.org/microrna/getGeneForm.do), and Pita (genie.weiz-
mann.ac.il/pubs/mir07/mir07_data.html). We only considered as
potential mRNA targets those who were predicted by three of
these algorithms. Gene ontology and cellular pathway analysis
altered by the aberrant expression of the microRNAs was done
using the Reactome [55] and DIANA lab software [56], which
obtained the information from TargetScan 5 (2009) [57], PicTar
4-way (2007) [58], and visualized in Wikipathways [59].
Biological replication of differentially expressed
microRNAs
Independent RT-PCR analysis using specific TaqMan micro-
RNA assays was performed to replicate the expression of 17
microRNAs (miR-10b, miR-668, miR-431, miR-136*, miR-129-
3p, miR-488, miR-99a, miR25*, miR-27a, miR149*, miR-206,
miR492, miR-21) in an independent set of 20 normal and 55
fresh-frozen breast tumor samples. All assays were run in
duplicate. These microRNAs were chosen based on differential
expression between tumors and normal tissues and statistical
confidence. Of this set of miRNAs, there is no previous
information regarding the expression of miR- 136*, miR-99a,
miR-488 and miR-668, in breast tumors. MiR-184, miR-24, miR-
492 and miR-326, whose expression did not changed significantly
between tumors and normal tissues in the TLDA assay, were
selected as experimental controls, while RNU-44 and RNU-48
were used as endogenous controls for normalization.
Conservation of mature miRNA/miRNA* sequence
analysis
We made a comprehensive computational survey of miRNA
conservation sequence across 5 animal genomes: Gasterosteus
aculeatus (fish), Xenopus tropicalis (frog), Anolis carolinensis (reptile),
Gallus gallus (bird), Monodelphis domestica (marsupial), Mus musculus
(rodent) and Homo sapiens. We used the miROrtho database
[60], to make multiple ortholog alignments and evaluate the
conservation of the RNA secondary structure. For this analysis, we
blasted the hairpin structure sequence of each miRNA obtained
from miRBase.
Correlation between miRNA profiles in FFPE tissues and
fresh frozen samples
Four fresh-frozen samples and their corresponding FFPE tissues
obtained from the same patient’s tumor were analyzed with the
TLDA platform (plate A) to evaluate the effect of formalin fixation
and paraffin embedding process on the microRNA expression
patterns. Correlation between the fresh-frozen and the FFPE
results was evaluated using Spearman Correlation. For all
statistical analysis, the log transformed delta Ct values were used.
Non-supervised clustering analysis was done using Euclidian
distance and average linkage including all samples. The results
were visualized in a heat map.
In conlusion, our analysis identified a set of microRNAs with no
previously known involvement in breast cancer, whose altered
expression target relevant cellular pathways. The identification of
a set of evolutionary conserved microRNA* showing differential
expression between the normal and tumor tissues interesting
research opportunities to study the role of the passenger
microRNA strand in cancer.
Supporting Information
Figure S1 Principal Component analysis based in the
miRNA differential expression profile. The two most
informative components were plotted. Clustering of the normal
tissues and tumor tissues is observed.
(TIF)
Figure S2 Signal correlation Plot between the biological
and technical samples analyzed. A) Scarlet plots of the
correlation between expression values between control samples
evaluated by Spearman correlation (correlation: 100-93%) B)
Scarlet plots of the correlation between expression values between
breast tumor tissues (correlation: 100-84%).
(TIF)
Figure S3 Unsupervised hierarchical clustering using
the differentially expressed miRNAs between Estrogen
Receptor (ER) positive and ER negative samples. The
heatmap (Spearman correlation, Euclidean distance, complete
linkage) represents Delta Ct values. Heat map colors correspond to
miRNA expression as indicated in the color key: red over-
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and Dark blue line: ER positive.
(TIF)
Figure S4 Unsupervised hierarchical clustering using
the differentially expressed miRNAs in Progesterone
Receptor (PR) positive and PR negative samples. The
heatmap (Spearman correlation, Euclidean distance, complete
linkage) represents Delta Ct values. Heat map colors correspond to
miRNA expression as indicated in the color key: red over-
expressed and green down-regulated. Salmon line: PR negative
and Dark blue line: PR positive.
(TIF)
Figure S5 Analysis of evolutionary conservation by
multiple sequence aligments. The upper panel shows
sequence alignments with the consensus hairpin sequence and
the conservation profile displayed in the grey histogram. The
mature miRNA sequence is underlined. The miRNA sequence is
located at the left side of the aligned sequences while the miRNA*
is at the right. The inferior panel shows the consensus secondary
structure of the orthologous sequence. The color-coding of the
nucleotide changes is shown in the box.
(TIF)
Figure S6 Consensus secondary structure of the ortho-
logous sequence. Percentage of the miRNAs nucleotide
subtitutions in each miRNA/miRNA* of the seed regions (2–8
nucleotide). The blue bars represents the miRNA strand, the red
bars represents the miRNA* strand.
(TIF)
Figure S7 Chromosome 14 and policistronic miRNAs.
A) Number of miRNAs included in the expression profile and their
chromosomal location. Asterisks indicate chromosomes with the
higher numbers of differentially expressed miRNAs. B) micro-
RNAs with differential expression in chromosome 14. Green lines
indicate the miRNAs that are included in our differential profile.
(TIF)
Figure S8 Gene Ontology analysis of the pathways
affected by the differentially expressed novel micro-
RNAs. Enrichment analysis made with the mRNA targets of the
not previously reported miRNAs. Yellow circles indicate the
pathways associated with breast cancer.
(TIF)
Table S1 Complete list of the 130 differentially ex-
pressed miRNAs between normal and breast tumors.
(DOC)
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